Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Veritas In Silico Inc. ( ($JP:130A) ) has issued an update. Veritas In Silico has filed a substance patent application in Japan for a ...

Hawaasa Afrikaa Kibbaa Afrikaanars Tiraamp ofitti fudhachuu fedhan maaltu kakaase? 'BBC Africa Eye' qorateera.

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...